Smith 2 , Julian Symons 2 , Andreas Jekle 2,4 and Tongfei Wu 1 , (1)Aligos Belgium BV, Leuven, Belgium, (2)Aligos Therapeutics, Inc., South San Francisco, CA, USA, (3)Aligos Therapeutics, Inc., (4)Aligos Therapeutics, Inc., South San Francisco, CA, USA, South San Francisco, CA, United States Background: PD-1/PD-L1 antibody-based therapies have demonstrated success in the treatment of liver cancer and have exhibited potential for effecting functional cure of chronic hepatitis B (CHB)
As an estrogen blocker and antioxidant, DIM is a powerful aromatase inhibitor.* PREMIUM QUALITY: Our capsules are formulated non-GMO, third-party tested, and made to the highest possible standards in a cGMP facility.
Get a unique 5% discount on top of the wholesale price for your first order
doi: 10.1080/08923970701284664 13 AndersonHLBrodskyIEMangalmurtiNS